Brasil
 
O conteúdo desse portal pode ser acessível em Libras usando o VLibras

Evidence on phytotherapy for the treatment of long-term COVID in the scope of primary health care in the SUS

    Teacher Leandro da Silva Fabre

    Federal University of Juiz de Fora (UFJF), Faculty of Pharmacy, Department of Pharmaceutical Sciences, University Campus, Rua José Lourenço Kelmer, São Pedro, CEP 36036-900, Juiz de Fora, MG, Brazil.

    OrcID https://orcid.org/0000-0001-6630-3037

    IT Technician, Nursing, Clinical Analysis and Pharmacy. Interned at Juiz de Fora City Hall - MG. Graduated in Pharmacy from Universidade Presidente Antônio Carlos (2020). He worked in Computer Science and Citizenship Laboratory Monitoring, in FADEP - UFJF data verification, in Clinical, Emergency and Hospital Intensive Unit Nursing, in the Industrial Biological Safety and Clinical Analysis Laboratory. He also worked in several departments of Juiz de Fora City Hall, such as the Secretary of Health, Education and Undersecretary of Technology and Information.

    Dr. Valéria Dibo

    Federal University of Juiz de Fora (UFJF), Faculty of Pharmacy, Department of Pharmaceutical Sciences, University Campus, Rua José Lourenço Kelmer, São Pedro, CEP 36036-900, Juiz de Fora, MG, Brazil.

    OrcID https://orcid.org/0000-0002-8063-3216

    Graduated in Pharmacy from the Federal University of Juiz de Fora (1990). He is currently a higher-level technician at Juiz de Fora City Hall, working in Urban and Rural Primary Care. He has experience in the area of ​​Biochemistry, Pharmacy, with an emphasis on clinical Pharmacy, pharmaceutical assistance and attention. Currently undergoing professional development as a Master's student in the Postgraduate Program in Pharmaceutical Sciences at the Faculty of Pharmacy of UFJF

    Dr. Maurilio de Souza Cazarim

    Federal University of Juiz de Fora (UFJF), Faculty of Pharmacy, Department of Pharmaceutical Sciences, University Campus, Rua José Lourenço Kelmer, São Pedro, CEP 36036-900, Juiz de Fora, MG, Brazil.

    OrcID https://orcid.org/0000-0002-2826-5903

    Pharmacist, Adjunct Professor at the Federal University of Juiz de Fora, Juiz de Fora-MG, Brazil (2020). Post-doctorate in Public Health at the Faculty of Medicine of Ribeirão Preto, University of São Paulo - FMRP/USP (in progress). Permanent professor of the Postgraduate Program in Nursing (PPGEn) at UFJF (2023). Member of the Health Technology Assessment Center of the UFJF University Hospital and the Ribeirão Preto Hospital das Clínicas (NATS HU-UFJF and NATS HCFMRP-USP) (2023). Associate Editor of the Brazilian Journal of Health and Pharmacy - BJHP (2023). Advisory member of the UFJF Research Assessment Committee (2022). Member of the Research Ethics Committee of the UFJF University Hospital (2022). Technical consultant for PROADI - SUS for the process of implementing pharmaceutical care in Brazilian municipalities, 2019-2020. P.hD., doctorate from the Pharmaceutical Sciences program of the postgraduate course of the Faculty of Pharmaceutical Sciences of Ribeirão Preto, University of São Paulo (FCFRP/USP) / University of Glasgow, carried out in the Health Economics Health Technology Assessment (HEHTA), under supervision of professor PhD.Olívia Wu, BEPE/FAPESP scholarship (2019). MSc., FAPESP scholarship holder for a master's degree in Pharmaceutical Sciences (2016) from FCFRP/USP, with in-depth analysis of pharmacoeconomic analyzes and the development and clinical impact of pharmaceutical care. Specialist in public health (2013) from the Comprehensive Health Care Program - Faculty of Medicine of Ribeirão Preto, University of São Paulo (Multiprofessional Residency), 5760 hours. BSc., graduated in Pharmacy (2010), generalist curriculum, from the Federal University of Juiz de Fora, where he completed two years of scientific initiation covering lines of research relating to Pharmaceutical Assistance and Study of Medication Use. Researcher in the area of ​​Pharmaceutical Assistance and Clinical Pharmacy, with expertise in conducting observational epidemiological studies and carrying out different clinical trial designs. Development of research in the areas of health economics / Assessment of Health Technologies and Pharmacoeconomics to strengthen Evidence-Based Health, considering for this the improvement of skills in the construction of systematic reviews with meta-analysis; Markov modeling and decision tree models; assessment of health technologies in the global context; survival analysis combined with economic analysis; data analysis for health economics; applicability of pharmacoeconomic studies in MCDA analyses.

Keywords

Abstract

About 10% to 20% of patients considered cured of COVID-19 may have changes in the body that lead them to develop COVID-19. Therapeutic alternatives for treatment have been applied in post-COVID-19 clinical management, phytotherapy stands out as an important clinical path. The objective of this study was to carry out a descriptive analysis on the use and application of herbal medicines in the portion of the population affected by COVID-long. This is a narrative review, with data collection in an exploratory way by expertise in the clinical and phytotherapy area. The qualitative approach was carried out from the perspective of identifying and applying the use of herbal medicines within the scope of Primary Health Care (PHC) for the treatment of symptoms in COVID-long. The findings signal an important investigative niche for short- to medium-term treatments in long-term COVID-19. Uncaria tomentosa for cough treatment, Ginkgo biloba for cardiovascular involvement; Mangifera indica Linneaus for neuromuscular and Valeriana officinalis for the Central Nervous System. Some studies may suggest the standardization of herbal medicines in the Unified Health System for their use in PHC as an adjuvant to treatment associated with allopathic medicines.

References

  1. Lana RM, Coelho FC, Gomes MFC, Cruz OG, Bastos LS, Villela DAM et al. Emergência do novo coronavírus (SARS-CoV-2) e o papel de uma vigilância nacional em saúde oportuna e efetiva. Cad Saúde Públ. [Internet]. 2020 Mar 13; 36: e00019620. Disponível em: [https://doi.org/10.1590/0102-311x00019620].
  2. World Health Organization – WHO. COVID-19 dashboard. [Internet]. World Health Organization. 2022. Disponível em: [https://covid19.who.int/].
  3. Amazonas LF, Figueiredo EFG. Uma revisão sobre o uso das plantas medicinais como tratamento da COVID-19 e a importância do profissional farmacêutico no estado do Amazonas. Res Soc Develop. 2021 Nov 22; 10(15): e406101523451. Disponível em: [https://doi.org/10.33448/rsd-v10i15.23451].
  4. World Health Organization-WHO. Supports scientifically-proven traditional medicine. [Internet]. WHO | Regional Office for África. [acesso em: 2022 Jul 29]. Disponível em: [https://www.afro.who.int/news/who-supports-scientifically-proven-traditional-medicine].
  5. Pinto EG, Cavalcante FSA, Lima RA. A fitoterapia no tratamento de pele: um estudo bibliográfico. Biodiversidade [Internet]. 2020 Jul 26; 19(3): 188-197. Disponível em: [https://periodicoscientificos.ufmt.br/ojs/index.php/biodiversidade/article/view/10827].
  6. Araújo BC, Silva LALB, Melo RC, Domene FM, Silva JL, Milhomens LM et al. Manifestações clínicas e laboratoriais pós-covid [Internet]. Disponível em: [https://fi-admin.bvsalud.org/document/view/4ey9s].
  7. Dourado P, Ramos A, Lima A, Vieira L. Síndrome pós-COVID-19 [Internet]. 2020. Disponível em: [https://goias.gov.br/saude/].
  8. Post-COVID-19 global health strategies: the need for an interdisciplinary approach. Aging Clinical Exper Res. 2020 Jun 11; 32(8): 1613–1620. [https://doi.org/10.1007/s40520-020-01616-x].
  9. Comunicação oficial - ASSOBRAFIR COVID-19. Fisioterapia na atenção primária à saúde recomendações para a atuação dos fisioterapeutas no âmbito da atenção primária à saúde (aps) de pacientes suspeitos ou diagnosticados com COVID-19 * †. 2020. [Internet]. Disponível em: [https://assobrafir.com.br/wp-content/uploads/2020/06/ASSOBRAFIR_COVID-19_APS_2020.06.01.pdf].
  10. Wu M. Síndrome pós-Covid-19 – Revisão de Literatura. Rev Biociênc. [Internet]. 2021 Aug 13; 27(1): 1–14. [acesso em: 2022 Jul 29]. Disponível em: [http://periodicos.unitau.br/ojs/index.php/biociencias/article/view/3313/2034].
  11. Campos MR, Schramm JMA, Emmerick ICM, Rodrigues JM, Avelar FG, Pimentel TG. Carga de doença da COVID-19 e de suas complicações agudas e crônicas: reflexões sobre a mensuração (DALY) e perspectivas no Sistema Único de Saúde. Cad Saúde Públ [Internet]. 2020; 36(11): e00148920. [acesso em: 2021 Apr. 18]. Disponível em: [https://doi.org/10.1590/0102-311x00148920].
  12. Covid longa pode deixar sequelas que duram muitos meses [Internet]. Rev Pesq Fapesp. Disponível em: [https://revistapesquisa.fapesp.br/covid-longa-pode-deixar-sequelas-que-duram-muitos-meses/].
  13. Bizarri CHB, Rezende MA, Mattos AER, Nóbrega AB, Villas Bôas GK. Do quinino aos antimaláricos sintéticos: o conhecimento das plantas medicinais como estratégia potencial na terapia da CoVID-19. Rev Fitos. [Internet]. 2021 Sep 30; 15(3): 366–84. [acesso em: 2022 Jul 29] Disponível em: [https://doi.org/10.32712/2446-4775.2021.1086].
  14. Mancuzo EV, Marinho CC, Machado-Coelho GLL, Batista AP, Oliveira JF, Andrade BH et al. Lung function of patients hospitalized with COVID-19 at 45 days after hospital discharge: first report of a prospective multicenter study in Brazil. J Bras Pneumol. Publicação oficial da sociedade brasileira de pneumologia e tisilogia. [Internet]. 2021; 47(6): e20210162. [acesso em: 2022 Sep 7]. Available from: [https://pubmed.ncbi.nlm.nih.gov/34932718/].
  15. Teixeira-Vaz A, Rocha JA, Reis DA, Oliveira M, Moreira TS, Silva AI et al. COVID-19 crítico e disfunção neurológica - uma análise comparativa direta entre o SARS-CoV-2 e outros agentes infecciosos. Rev Bras Terapia Intens. 2022; 34(3): 2022Jul; 34(3): 342–50. [https://doi.org/10.5935/0103-507X.20220229-pt].
  16. Costa IBSS, Bittar CS, Rizk SI, Araújo Filho AE, Santos KAQ, Machado TIV et al. The Heart and COVID-19: What Cardiologists Need to Know. Arq Bras Cardiol. [Internet]. 2020 May 1; 114(5): 805–16. Disponível em: [https://www.scielo.br/scielo.php?pid=S0066-782X2020005007208&script=sci_arttext].
  17. Pecly IMD, Azevedo RB, Muxfeldt ES, Botelho BG, Albuquerque GG, Diniz PHP et al. A review of Covid-19 and acute kidney injury: from pathophysiology to clinical results. Braz J Nephrol. 2021 May 28; 43(4): 551–571. [https://doi.org/10.1590/2175-8239-jbn-2020-0204].
  18. Alves EV, Beber BC. Self-perception of cognitive sequels in post-COVID-19 individuals. Dem Neuropsychol. [Internet]. 2023; 17: e20220080. [acesso em: 2023 jun. 5]. Disponível em: [https://doi.org/10.1590/1980-5764-DN-2022-0080].
  19. Figueirêdo MMLG, Forte AFGF, Souto JD, Aquino CC. Revisão de literatura: alterações intestinais em idosos que foram acometidos pela COVID-19 [Internet]. Doity. [acesso em: 2023 jun. 5]. Disponível em: [https://doity.com.br/anais/conexaounifametro2022/trabalho/262699].
  20. Yepes-Pérez AF, Herrera-Calderon O, Quintero-Saumeth J. Uncaria tomentosa (cat’s claw): a promising herbal medicine against SARS-CoV-2/ACE-2 junction and SARS-CoV-2 spike protein based on molecular modeling. J Biomolec Struct Dynam. 2020 Oct 29; 40(5): 2227-2243. [https://doi.org/10.1080/07391102.2020.1837676].
  21. Coelho ACB, Borges BF, Pinheiro ECC, Nunes VLND, Khan A, Fernandes RMT. Análise dos metabólitos secundários da Mangifera indica linneaus como possibilidade de tratamento alternativo para a síndrome pós-covid-19. Braz J Develop. 2021; 7(10): 95673–95692. Disponível em: [https://doi.org/10.34117/bjdv7n10-65] .
  22. Al‐kuraishy HM, Al‐Gareeb AI, Kaushik A, Kujawska M, Batiha GE. Ginkgo biloba in the management of the COVID‐19 severity. Archiv der Pharmazie. 2022 Jun 7; 355(10): 2200188.
  23. Nascimento EL, Watanabe M, Fonseca CD, Schlottfeldt FS, Vattimo MFF. Efeito renoprotetor do Echinodorus macrophyllus na lesão renal induzida. Acta Paulista Enfer. [Internet]. 2014; 27: 12–7. [acesso em: 2023 Jun 5]. Disponível em: https://www.scielo.br/j/ape/a/b5rbW68qs5FrZjbxZd9pvjv/?lang=pt
  24. Pessolato JP, Rodrigues SP, Alvez DS. Avaliação do consumo de valeriana e passiflora durante pandemia por COVID-19 [Internet]. 2021; 4(2): 5589–5609. [acesso em: 2022 Jul 16]. Disponível em: [https://doi.org/10.34119/bjhrv4n2-126].
  25. Jezova D, Karailiev P, Karailievova L, Puhova A, Murck H. Food Enrichment with Glycyrrhiza glabra Extract Suppresses ACE2 mRNA and Protein Expression in Rats—Possible Implications for COVID-19. Nutrients. [Internet]. 2021 Jul 6; 13(7): 2321. [acesso em: 2022 Apr 19]. Disponível em: [https://doi.org/10.3390/nu13072321].
  26. Oliveira DF, Godoy ALR de, Cavalaro V, Bella LM, Oliveira CR. Fitoterápicos candidatos a combater sintomas da COVID-19 e seus possíveis mecanismos de ação. Braz J Health Pharm. [Internet]. 2020 Dec 14; 2(4): 10–9. Disponível em: [https://bjhp.crfmg.org.br/crfmg/article/view/108/72].
  27. Franco JVV, Oliveira LCL de, Dias DVR, Azeredo JPS, Fonseca JB. Uma revisão sobre o uso das plantas medicinais no tratamento e prevenção da COVID-19. Res Soc Develop [Internet]. 2022 Jun 8; 11(8): e4711830658–e4711830658. [acesso em: 2022 Jul 28] Disponível em: [https://rsdjournal.org/index.php/rsd/article/view/30658/26258].
  28. Tsampasian V, Elghazaly H, Chattopadhyay R, Debski M, Naing TKP, Garg P et al. Risk Factors Associated With Post−COVID-19 Condition. JAMA Inter Medic. [Internet]. 2023 Mar 23; Disponível em: [https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2802877].
  29. Costa BAD, Silva L, Mendes M, Karmann Í, Campos B, Nogueira M et al. Anxiety And Depression Are Associated With Limbic Atrophy And Severe Disruption Of Brain Functional Connectivity After Mild COVID-19 Infection (S21.007). Neurology. [Internet]. 2023 Apr 25; 100(17 Suppl. 2). [acesso em: 2023 Jun 16]. Disponível em: [https://n.neurology.org/content/100/17_Supplement_2/1998].
  30. Silva FTM, Ferreira D, Santana GB, Santos KMG, França EFG. Utilização da fitoterapia para redução da ansiedade frente a pandemia por SARS-COV-2. Rev Fitos. 2022 Aug 1; 16(4): 541-550. Disponível em: [https://doi.org/10.32712/2446-4775.2022.1404].
PDF (Portuguese)
HTML (Portuguese)
XML (Portuguese)
Save bookmark

Author(s)

  • Teacher Leandro da Silva Fabre
    Federal University of Juiz de Fora (UFJF), Faculty of Pharmacy, Department of Pharmaceutical Sciences, University Campus, Rua José Lourenço Kelmer, São Pedro, CEP 36036-900, Juiz de Fora, MG, Brazil.
    https://orcid.org/0000-0001-6630-3037
  • Dr. Valéria Dibo
    Federal University of Juiz de Fora (UFJF), Faculty of Pharmacy, Department of Pharmaceutical Sciences, University Campus, Rua José Lourenço Kelmer, São Pedro, CEP 36036-900, Juiz de Fora, MG, Brazil.
    https://orcid.org/0000-0002-8063-3216
  • Dr. Maurilio de Souza Cazarim
    Federal University of Juiz de Fora (UFJF), Faculty of Pharmacy, Department of Pharmaceutical Sciences, University Campus, Rua José Lourenço Kelmer, São Pedro, CEP 36036-900, Juiz de Fora, MG, Brazil.
    https://orcid.org/0000-0002-2826-5903

Metrics

  • Article viewed 97 time(s)

How to Cite

1.
Evidence on phytotherapy for the treatment of long-term COVID in the scope of primary health care in the SUS. Rev Fitos [Internet]. 2024 Jul. 17 [cited 2025 Apr. 3];18:e1511. Available from: https://revistafitos.far.fiocruz.br/index.php/revista-fitos/article/view/1511
Crossref
Scopus
Google Scholar
Europe PMC
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Copyright (c) 2024 Revista Fitos

Report an error
Conteúdo acessível em Libras usando o VLibras Widget com opções dos Avatares Ícaro, Hosana ou Guga. Conteúdo acessível em Libras usando o VLibras Widget com opções dos Avatares Ícaro, Hosana ou Guga.